[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nras-g12a\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nras-g12a":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":18,"phases":4,"briefSummary":19,"conditions":20,"keywords":36,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":50,"locationsCount":4},"100599360",false,"NCT07083479","Expanded Access Protocol of ELI-002-102 in Subjects With KRAS\u002FNRAS Mutated Pancreatic Ductal Adenocarcinoma","Expanded Access Protocol for ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)\u002FNeuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC)","AMPLIFY-EAP","Inclusion Criteria:\n\n* Has at least 1 of the 7 KRAS\u002FNRAS mutated alleles (G12D, G12R, G12V, G12A, G12C, G12S, G13D)\n* The following must be met: (1) the patient has no alternative therapy to diagnose, monitor, or treat the disease or condition; (2) enrollment in a clinical trial is not possible; and (3) the potential benefit to the patient justifies the potential risks of treatment.\n* Screening CT scan negative for recurrent disease\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n\nExclusion Criteria:\n\n* Use of immunosuppressive drugs\n* Known brain metastases","ALL","18 Years","EXPANDED_ACCESS","This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \\[Amph-CpG-7909\\] plus a mixture of lipid-conjugated peptide-based antigens \\[Amph-Peptides 7P\\]) as adjuvant treatment in patients with KRAS\u002FNRAS-mutated pancreatic ductal adenocarcinoma who are at high risk for relapse (ie, presence of isolated tumor cells in a patient whose primary tumor has been removed and is currently without clinical signs of disease). This protocol builds on the experience being obtained with ELI-002 7P (with Amph-Peptides G12D, G12R, G12V, G12A, G12C, G12S, G13D), which is being studied in protocol ELI-002-201.",[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35],"Pancreatic Ductal Adenocarcinoma","KRAS G12D","KRAS G12V","KRAS G12S","KRAS G12A","KRAS G12C","KRAS G12R","KRAS G13D","NRAS G12D","NRAS G12V","NRAS G12S","NRAS G12A","NRAS G12C","NRAS G12R","NRAS G13D",[37,38,39,40,41,42,43,44],"Pancreatic ductal adenocarcinoma (PDAC)","Kirsten rat sarcoma (KRAS)","Neuroblastoma ras viral oncogene homolog (NRAS)","Adjuvant therapy","Immunotherapy","Vaccine therapy","Expanded access","Expandd access protocol (EAP)","AVAILABLE","2026-05-18",{"date":48,"type":49},"2026-05-19","ACTUAL",{"name":51,"class":52},"Elicio Therapeutics","INDUSTRY",""]